ArticleThe American journal of case reports2025
Ocular Involvement in Post-Transplantation Lymphoproliferative Disorder: A Rare Case with Rituximab Hypersensitivity.
Article in The American journal of case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Post-transplantation lymphoproliferative disorder (PTLD) is a heterogeneous group of lymphoid proliferative conditions that occur in transplant recipients under sustained immunosuppression. Rituximab is widely used as first-line therapy for PTLD. However, hypersensitivity reactions to rituximab are rarely reported in pediatric patients. CASE REPORT A 1-year-old boy underwent living-donor liver transplantation for biliary atresia using his mother's graft. Six years after transplantation, he presented with mild graft rejection and abnormal liver function tests. Cervical lymphadenopathy was also noted, accompanied by elevated Epstein-Barr virus (EBV) DNA levels. Following tacrolimus dose reduction, EBV DNA levels gradually declined. Two years later, he developed progressive right-eye visual impairment, and evaluation confirmed intraocular PTLD. Fundoscopy showed a mass in the iris-ciliary body of the right eye and mild elevation in the left eye. Despite administration of intraocular methotrexate and surgical intervention, the disease progressed. Rituximab (RTX) was discontinued due to hypersensitivity reactions. Subsequently, the patient received obinutuzumab, a third-generation anti-CD20 monoclonal antibody, which was well tolerated and resulted in undetectable EBV DNA levels and a reduction of intraocular inflammation. The patient is currently maintained off immunosuppressive therapy without evidence of graft rejection. CONCLUSIONS Intraocular PTLD is a rare condition that must be distinguished from other ocular pathologies in liver transplant recipients, and clinicians should suspect intraocular PTLD in such cases. Our summary integrates clinical insights regarding the manifestations and ocular involvement of intraocular PTLD. Patients allergic to rituximab may benefit from third-generation anti-CD20 monoclonal antibodies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.